GeneDx Holdings Corp. (WGS) News
Follow GeneDx Holdings Corp. (WGS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
GeneDx Reports Q3 2026 Revenue of $123.1 Million, Adjusted EPS of $0.28
Third-quarter revenue slightly exceeded FactSet’s $122.9 million estimate, while adjusted EPS of $0.28 topped the $0.07 estimate. GeneDx expects fourth-quarter revenue of $135.0 million and reiterated full-year revenue g
EQUITY | Nov 09, 2026, 10:33 PM UTC
M
GeneDx Q3 Revenue Beats on Higher Exome and Genome Test Volumes
EQUITY | Nov 09, 2026, 09:21 PM UTC
M
GeneDx Reports Third-Quarter 2026 Financial Results
GeneDx Holdings reported financial results for the third quarter of 2026.
EQUITY | Nov 09, 2026, 09:06 PM UTC
L
GeneDx and Beren Therapeutics launch NPC GenomeComplete testing program
GeneDx announced a collaboration with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program, offering no-cost comprehensive genome sequencing for eligible Niemann-Pick disease type C patien
EQUITY | Sep 09, 2026, 12:30 PM UTC
M
WGS Q2 volumes rise 32% on new markets and automation
WGS said Q2 volumes grew 32%, attributing momentum to core channels and expansion into primary care and prenatal markets underway. Management cited untapped potential in geneticists, pediatric neurology and NICU, plus co
EQUITY | Sep 08, 2026, 07:45 PM UTC
L
WGS reports Q2 volume growth of 32%
WGS said Q2 volume grew 32%, with initiatives underway to expand and improve margins. Management cited core-market strength while targeting additional potential in geneticists, pediatric neurology and NICU.
EQUITY | Sep 08, 2026, 07:08 PM UTC
L
GeneDx publishes study on rapid genome sequencing in pediatric care
GeneDx says a study published in Genetics in Medicine shows hospital-wide first-tier rapid genome sequencing improved diagnostic rates, reduced time to diagnosis, and enhanced operational efficiency in pediatric inpatien
EQUITY | Aug 24, 2026, 12:34 PM UTC
L
GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $478.367M Est
GeneDx Holdings (NASDAQ: WGS ) affirms FY2026 sales outlook from $475.000 million-$490.000 million to $475.000 million-$490.000 million vs $478.367 million estimate.
EARNINGS | Aug 03, 2026, 08:19 PM UTC
L
WGS - GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
WGS - GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
EQUITY | Jul 31, 2026, 08:08 AM UTC
L
WGS WGS - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS - Click For R
WGS WGS - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
REGULATION | Jul 30, 2026, 02:08 PM UTC
L
WGS - HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud
WGS - HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
EQUITY | Jul 28, 2026, 02:10 PM UTC
L
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, July 06, 2026 (GLOBE NEWSWIRE) -
EQUITY | Jul 06, 2026, 02:14 PM UTC
L
WGS INVESTORS: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to L
SAN DIEGO, July 05, 2026 (GLOBE NEWSWIRE) -
EQUITY | Jul 05, 2026, 04:50 PM UTC
L
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) -- Hagens Berman (HBSS), a national leader in securities li
EQUITY | Jul 03, 2026, 06:21 PM UTC
L
GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Ch
Did you buy WGS securities between April 16, 2025, and May 4, 2026
EQUITY | Jul 03, 2026, 05:05 PM UTC
L
WGS LAWSUIT ALERT: Levi & Korsinsky Notifies GeneDx Holdings Corp. Investors - Lead Plaintiff Deadline August 3, 2026
NEW YORK, NY / / July 3, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise
EQUITY | Jul 03, 2026, 04:55 PM UTC
M
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74
Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ: WGS ) with a Buy and raises the price target from $70 to $74.
EQUITY | Jun 29, 2026, 02:07 PM UTC
M
WGS: Piper Sandler Raises Target
Piper Sandler maintains overweight rating on GeneDx Holdings and raises price target to $63
EQUITY | Jun 23, 2026, 04:42 PM UTC